Search CTL/CD8+ T-Cell Epitope Database

Found 5 matching records:

Displaying record number 56197

Download this epitope record as JSON.

HXB2 Location	gp160(50-59) gp120(50-59) DNA(6372..6401)	gp160 Epitope Map
Author Location	Env(61-)
Epitope	`TTLFCASDAK`	Epitope Alignment
Species (MHC/HLA)	human(A*03:01)
Immunogen	vaccine
Country	Botswana, United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	DNA, polyepitope
Vaccine strain	multiple epitope immunogen

Notes

This is a trial of a multi-epitope DNA vaccine that included 21 CTL epitopes, which are conserved among clades A,B,C,D and CRFs and are supertype binding peptides of A1, A3 and B7 supertypes. Participants were from US and Botswana.
The vaccine was safe and well-tolerated, but the rate of CTL induction was low. CD8+ responses (and no CD4+ responses) were detected in 3/26 subjects using chromium release assay and in 2/42 subjects using IFN-γ ELISPOT assay.
This epitope was included in the vaccine.

References

Gorse2008a Geoffrey J. Gorse, Lindsey R. Baden, Margaret Wecker, Mark J. Newman, Guido Ferrari, Kent J. Weinhold, Brian D. Livingston, Tonya L. Villafana, Hongli Li, Elizabeth Noonan, Nina D. Russell, and HIV Vaccine Trials Network. Safety and Immunogenicity of Cytotoxic T-Lymphocyte Poly-Epitope, DNA Plasmid (EP HIV-1090) Vaccine in Healthy, Human Immunodeficiency Virus Type 1 (HIV-1)-Uninfected Adults. Vaccine, 26(2):215-223, 10 Jan 2008. PubMed ID: 18055072. Show all entries for this paper.

Displaying record number 55129

Download this epitope record as JSON.

HXB2 Location	gp160(50-59) gp120(50-59) DNA(6372..6401)	gp160 Epitope Map
Author Location	gp120(50-59)
Epitope	`TTLFCASDAK`	Epitope Alignment
		Show epitope variants
Species (MHC/HLA)	human(A3)
Immunogen
Experimental methods
Keywords	subtype comparisons, viral fitness and reversion

Notes

Determined the frequencies of known CD8+ and CD4+ Env epitope sequences among Brazilian HIV sequences of various subtypes.
Present in 46/51 Brazilian HIV sequences.

References

Queiroz2007 Artur Trancoso Lopo de Queiroz, Luciane Amorim Santos, Domingos Ramon Moreau, Tulio de Oliveira, David I. Watkins, Bernardo Galvão-Castro, and Luiz Carlos Junior Alcantara. Identification and Characterization of Previously Described Epitopes in HIV-1 Subtypes B, C, F and BF in Brazil. Braz. J. Infect. Dis., 11(1):27-30, Feb 2007. PubMed ID: 17625722. Show all entries for this paper.

Displaying record number 56540

Download this epitope record as JSON.

HXB2 Location	gp160(50-59) gp120(50-59) DNA(6372..6401)	gp160 Epitope Map
Author Location	Env
Epitope	`TTLFCASDAK`	Epitope Alignment
Epitope Name	Env61
Subtype	B
Species (MHC/HLA)	human(A3)
Immunogen	vaccine
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ
Keywords	vaccine antigen design

Vaccine Details

Vaccine type	DNA, polyepitope
Vaccine component	other

Notes

DNA vaccine EP HIV-1090 evaluation in patients receiving ART was done. This vaccine is composed of multiple CTL epitopes, all associated with certain HLA supertypes. Differences of CTL response rate in vaccine and placebo recipients however, was not significant.
TTLFCASDAK is an Env epitope encoded in the EP HIV-1090 polyepitope vaccine.

References

Wilson2008 Cara C. Wilson, Mark J. Newman, Brian D. Livingston, Samantha MaWhinney, Jeri E. Forster, Jim Scott, Robert T. Schooley, and Constance A. Benson. Clinical Phase 1 Testing of the Safety and Immunogenicity of an Epitope-Based DNA Vaccine in Human Immunodeficiency Virus Type 1-Infected Subjects Receiving Highly Active Antiretroviral Therapy. Clin. Vaccine Immunol., 15(6):986-994, Jun 2008. PubMed ID: 18400976. Show all entries for this paper.

Displaying record number 1610

Download this epitope record as JSON.

HXB2 Location	gp160(50-59) gp120(50-59) DNA(6372..6401)	gp160 Epitope Map
Author Location	Env(62-71)
Epitope	`TTLFCASDAK`	Epitope Alignment
Species (MHC/HLA)	human(A3 supertype)
Immunogen	HIV-1 infection
Experimental methods
Keywords	supertype, rate of progression

Notes

Long-term nonprogressors (LTNPs) had strong memory resting CD8+ T-cell responses against the majority of epitopes tested, (18 for the A2 supertype, 16 for the A3 supertype) while the effector cells of long-term nonprogressors recognized far fewer epitopes.
Progressors had memory resting CD8+ T-cells that recognized far fewer epitopes than LTNPs.
A positive correlation between effector CD8+ T-cells and plasma viremia and a negative correlation between CD8+ effector T-cells and CD4+ T-cells was observed, which may contribute to the inability of LTNPs to clear virus.
This epitope can bind 3/5 HLA-A3 supertype alleles (A*0301, A*1101, A*3101, A*3301 and A*6801).

References

Propato2001 A. Propato, E. Schiaffella, E. Vicenzi, V. Francavilla, L. Baloni, M. Paroli, L. Finocchi, N. Tanigaki, S. Ghezzi, R. Ferrara, R. Chesnut, B. Livingston, A. Sette, R. Paganelli, F. Aiuti, G. Poli, and V. Barnaba. Spreading of HIV-specific CD8+ T-cell repertoire in long-term nonprogressors and its role in the control of viral load and disease activity. Hum. Immunol., 62(6):561-76, Jun 2001. PubMed ID: 11390031. Show all entries for this paper.

Displaying record number 56519

Download this epitope record as JSON.

HXB2 Location	gp160(50-59) gp120(50-59) DNA(6372..6401)	gp160 Epitope Map
Author Location	Env
Epitope	`TTLFCASDAK`	Epitope Alignment
Epitope Name	Env61
Subtype	A, B, C, D
Species (MHC/HLA)	human, mouse(A3 supertype)
Immunogen	HIV-1 infection
Country	United States
Experimental methods	CD8 T-cell Elispot - IFNγ, Other
Keywords	binding affinity, supertype, vaccine-induced immune responses, HLA cross-presentation

Notes

21 supertype-A2, -A3 and -B7-restricted epitopes predicted to be immunogenic by HLA-peptide binding motifs and phenotypic frequency in individuals were recognized by HIV-1+ subjects in ELISpot assays and shown to bind with high affinity to minimum 3 HLA-alleles of the restricting supertype. These epitopes were included in DNA vaccine EP HIV-1090 that avoided immunodominant responses and did not restrict subject immunity to predicted HLA-type when tested in mice. Transgenic mice mounted a vaccine-response similar to that induced by ELISpot assay in humans.
Epitope TTLFCASDAK of the HLA-A3 supertype bound most strongly to HLA-A*1101, and -A*0301 and -A*6801 also to -A*3101 but not to -A*3301. It was conserved 100% in subtype A, 84% in B, 75% in C and 100% in subtype D. 2/23 HLA-A3 supertype expressing HIV-1+ subjects mounted a positive ELISpot response to Env61.

References

Wilson2003 Cara C. Wilson, Denise McKinney, Michelle Anders, Samantha MaWhinney, Jeri Forster, Claire Crimi, Scott Southwood, Alessandro Sette, Robert Chesnut, Mark J Newman, and Brian D Livingston. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1. J. Immunol., 171(10):5611-5623, 15 Nov 2003. PubMed ID: 14607970. Show all entries for this paper.